Remdesivir was the first antiviral agent to receive FDA authorization
for severe COVID-19 management, which restricts its use with severe
renal impairment due to concerns that active metabolites might
accumulate, causing renal toxicities. With limited treatment options,
available evidence on such patient groups is important to assess for
future safety.